Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 1999, p. 830-835, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
LY303366 Exhibits Rapid and Potent Fungicidal
Activity in Flow Cytometric Assays of Yeast Viability
Lisa J.
Green,*
Philip
Marder,
Larry L.
Mann,
Li-Chun
Chio, and
William
L.
Current
Lilly Research Laboratories, Lilly Corporate
Center, Indianapolis, Indiana 46285
Received 21 October 1998/Returned for modification 14 December
1998/Accepted 12 January 1999
 |
ABSTRACT |
LY303366 is a semisynthetic analog of the antifungal lipopeptide
echinocandin B that inhibits (1,3)-
-D-glucan
synthase and exhibits efficacy in animal models of human fungal
infections. In this study, we utilized flow cytometric analysis of
propidium iodide uptake, single-cell sorting, and standard
microbiological plating methods to study the antifungal effect of
LY303366 on Saccharomyces cerevisiae and Candida
albicans. Our data indicate that an initial 5-min pulse treatment
with LY303366 caused yeasts to take up propidium iodide and lose their
ability to grow. Amphotericin B and cilofungin required longer exposure
periods (30 and 180 min, respectively) and higher concentrations to
elicit these fungicidal effects. These two measurements of fungicidal
activity by LY303366 were highly correlated (r > 0.99) in concentration response and time course experiments. As further
validation, LY303366-treated yeasts that stained with propidium iodide
were unable to grow in single-cell-sorted cultures. Our data indicate
that LY303366 is potent and rapidly fungicidal for actively growing
yeasts. The potency and rapid action of this new fungicidal compound
suggest that LY303366 may be useful for antifungal therapy.
 |
INTRODUCTION |
New antifungal agents are urgently
needed to combat an increasing number of life-threatening, systemic
fungal infections. A fungicidal mode of action is highly desirable
since many patients requiring antifungal therapy are immunocompromised
(28). Enzymes required for fungal cell wall synthesis are
excellent targets for development of nontoxic fungicidal drugs.
Lipopeptide antifungals of the echinocandin class of compounds are
noncompetitive inhibitors of (1,3)-
-D-glucan synthase of
Candida spp. (24, 25) and Aspergillus
spp. (2) and are also effective against other pathogenic fungi, such as Pneumocystis carinii (1, 12).
Previous studies demonstrated the utility of flow cytometric technology
in detecting the rapid (3 h) fungicidal activity of cilofungin, a
narrow-spectrum semisynthetic echinocandin B (ECB) analog. Those
studies provided a positive correlation between flow cytometric
detection of fluorescent-dye uptake and classical microbiological
techniques (10) for measurement of fungicidal activity. In
the present study, we used the same methods and a single-cell-deposition technique to compare the fungicidal activities of amphotericin B (AMB) and cilofungin to that of a new, more potent
ECB analog, LY303366. We also varied the in vitro drug treatment
conditions to examine relationships between compound exposure time and
subsequent killing of target yeasts.
 |
MATERIALS AND METHODS |
Yeast cultures.
Candida albicans A26 (ATCC 90234) and
Saccharomyces cerevisiae YPH499 were obtained from Eli Lilly
& Co. (Indianapolis, Ind.) Infectious Disease Research stock cultures
and maintained on yeast-peptone-dextrose (YPD; Difco, Detroit, Mich.)
agar at 4°C. For experiments, organisms were grown overnight in
YPD broth in 32°C shaker bath and diluted to 2 × 106 cells/ml in fresh YPD broth just before use.
Antifungal agents.
Antifungal agents were diluted in their
appropriate solvents (listed below) to prepare 1.0-mg/ml stock
solutions. Cilofungin (Eli Lilly & Co.) was diluted in ethanol,
LY303366 (Eli Lilly & Co.) was dissolved in reagent-grade methanol, and
crystalline AMB (Sigma, St. Louis, Mo.) was dissolved in dimethyl
formamide. Fresh dilutions of compound in YPD broth were prepared for
each experiment.
Compound treatments.
Active cultures and experimental
compounds were both diluted in YPD broth (1 ml each), combined in
sterile 12- by 75-mm polypropylene test tubes, and placed in a 32°C
shaker bath for defined time intervals. For pulsed-compound-exposure
experiments, 2 ml of phosphate-buffered saline (PBS) was added to tubes
after pulsed exposure, the tubes were centrifuged for 5 min at 400 × g, and the supernatant was aspirated from these pulsed
cultures. The pulsed-exposure cells were then resuspended in 2.0 ml of
fresh YPD broth containing a drug vehicle, whereas the
continuous-exposure cells were resuspended in the existing broth
containing the drug and vehicle. Tubes were returned to the 32°C
shaker bath to complete a 3- or 5-h incubation period. In experiments
where cultures were exposed to drug for the last 5 min of the
experiment, 20 µl of a 100× drug solution was added to the 2-ml
culture, and further processing for propidium iodide (PI) staining,
sorting, or CFU assay began after the 5-min exposure.
PI staining and flow cytometric analysis.
For PI staining of
cultures, cells were pelleted by centrifugation for 5 min at 400 × g, the supernatant was discarded, and the cells were
resuspended in PI (Sigma) solution (25 µg/ml in PBS) for 20 min
at room temperature before analysis on an EPICS Elite flow cytometer
(Coulter Corp., Hialeah, Fla.). During flow cytometric analysis,
individual cells were detected and categorized by their forward-angle
and right-angle scatter of incident 488-nm laser light as displayed in
Fig. 1A. This light scatter data plot was
used to establish a gated region that excluded cell clusters (>2
cells) from the fluorescence analysis. The light scatter gated PI
fluorescence of individual cells was acquired by using a 630-nm band-pass filter (FL3) and displayed in single-parameter histograms (Fig. 1B through E). By using the cytometer's onboard software, the
fluorescence histograms were integrated to determine the percentage of
PI
(living) and PI+ (dead) yeast cells.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Flow cytometric evaluation of treated C. albicans cells that were stained with PI. Actively growing yeast
cultures were treated with fungicidal agents as described in the text,
mixed with PI, and analyzed on the flow cytometer. (A) Light scatter
gating region used for the analysis of red fluorescence of each sample.
FS, forward scatter; SS, side scatter. (B through E) Red fluorescence
histograms displaying the integrated percentage of PI+
cells. The treatments for the panels were medium only (control)
(B), 70% ethanol (C), LY303366 for 3 h (D), and LY303366
for a 5-min pulse (E).
|
|
Flow cytometric cell sorting.
Vehicle control or
compound-treated yeast cells were single-cell sorted with a Coulter
EPICS Elite ESP cell sorter as described below. For each test sample,
the light scatter data were acquired and used to establish a sorting
region that included only single cells and budding cells. By using the
cell sorter's capabilities, single cells or budding cells were
electrostatically deflected into individual microculture wells
containing 200 µl of YPD broth in 96-well tissue culture plates
(Becton Dickinson Labware, Franklin Lakes, N.J., item 3072). These
plates were incubated at 30°C without shaking for 48 h and then
visually inspected for yeast growth. The percentage of single cells
that formed visible colonies in wells (percent single-cell growth
[SCG%]) was determined as follows: (no. of wells with a visible
yeast colony after 48 h/total no. of wells inoculated by single-cell
deposition) × 100.
CFU assay.
Aliquots of cultures were removed just prior to
PI staining or sorting and serially diluted in PBS. Selected dilutions
were plated in duplicate on YPD agar. The plates were incubated for a
minimum of 48 h at 30°C, colonies were counted, and results were
expressed as the percent reduction in CFU per milliliter compared to
the growth in nontreated control cultures.
 |
RESULTS |
Effect of LY303366 on PI staining of yeast.
Antifungal effects
can be detected by flow cytometric analysis of PI-treated yeast cells
(10). Certain antifungal agents increase the PI staining of
yeast. The effects of two fungicidal agents on C. albicans from a representative experiment are displayed in Fig. 1.
Figure 1A shows the light scatter gating region used for analysis of
red fluorescence. In Fig. 1B, the PI fluorescence for untreated
C. albicans cultures illustrates the very dim
autofluorescence profile attained. Figures 1C and D display the PI
fluorescence for other treatments of C. albicans. All
cells that developed a PI fluorescence intensity greater than that
noted for the untreated control cells (Fig. 1B) were defined as
PI+. Treatment of cells with 70% ethanol (Fig. 1C) gave a
>100-fold increase in PI fluorescence intensity, resulting in
virtually all of the cells becoming PI+. Continuous
treatment of cultures with the minimal fungicidal concentration
(MFC), the lowest concentration of drug resulting in more than 99%
killing of cells, of LY303366 (for C. albicans, 0.01 µg/ml) for 3 h (Fig. 1D) resulted in 87.7% of the
C. albicans cells becoming PI+. Finally,
cultures that were pulse treated with LY303366 at the MFC for only 5 min (Fig. 1E), followed by one wash and further incubation in
compound-free broth for the remainder of the 3-h incubation, displayed
a similar percentage of PI+ cells (85.7%) as did those
that were continuously treated during the 3-h incubation. Virtually
identical results were obtained when S. cerevisiae
cells were similarly tested (data not shown).
Determination of SCG% of PI+ and PI
cultures.
S. cerevisiae cultures were treated with a
moderately potent concentration of LY303366 (0.02 µg/ml) for
3 h, stained with PI, and analyzed on the cytometer. Data from a
representative experiment are summarized in Fig.
2. From this PI fluorescence profile,
cell-sorting regions were established around PI
and
PI+ regions (Fig. 2). Single cells from these two regions
were deposited into microculture wells of 96-well plates and incubated
at 30°C for 48 h. The number of wells (out of 48 from each
condition per plate) that displayed positive yeast growth are shown in
Fig. 2. These data demonstrate that after treatment with LY303366, virtually all the Saccharomyces cells that stained with PI
were nonviable (SCG% = 4.2), while the PI
cells
exhibited a SCG% (95.8) equal to that of the untreated controls (96.0). These data also indicate that PI itself (in
the absence of fungicidal agents) does not alter yeast SCG%.
Similar results were obtained with C. albicans
(data not shown).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Single-cell sorting of cells treated with LY303366 and
stained with PI. Active cultures of S. cerevisiae were
treated with LY303366 (0.02 µg/ml) for 3 h and mixed with
PI. The cells were analyzed on the cytometer, and individual cells were
sorted into microwell cultures based on their red fluorescence
intensity as defined by regions M2 (PI ) and M1
(PI+). After 2 days of static incubation at 30°C, the
microwells were visually inspected for determination of cell growth.
The number of wells (out of 48 used) with S. cerevisiae
growth is displayed for each of three plates in this representative
experiment.
|
|
Concentration response of LY303366 on PI staining and single-cell
sorting.
We studied the effect of LY303366 concentration on
S. cerevisiae viability. In addition to studying the
effect of LY303366 on PI uptake, we also utilized a cell sorter to
confirm the fungicidal effect. This instrument facilitates automated,
selective single-yeast-cell deposition into microculture wells of a
96-well plate. In the first series of cell-sorting experiments, we
examined the effect of treatments of various concentrations of LY303366
on S. cerevisiae viability by using both the
PI-staining technique and single-cell sorting during the same
experiments. Results of these studies are displayed in Fig.
3. After a 3-h incubation with LY303366, the percentage of PI+ cells (Fig. 3A) increased with
increasing compound concentration. There was a concomitant
decrease in the SCG% in the wells, as determined by cell sorting (Fig.
3A), as the concentration of LY303366 increased. Linear-regression
analysis of this data (Fig. 3B) demonstrated a very high correlation
(r = 0.998) of effect for these two measurements of
cell viability. The same correlation was observed in experiments using
C. albicans (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
PI staining and SCG% for S. cerevisiae treated for 3 h with LY303366. (A) Active
yeast cultures were treated with twofold serial dilutions (0.005 to
0.16 µg/ml) of LY303366 and either stained with PI and flow
cytometrically analyzed ( ) or single-cell sorted for SCG%
determinations ( ). Each data point represents the mean ± 1 standard error of the mean (SEM) for four experiments. (B) Mean
SCG% and mean percentage of PI+ cells for each LY303366
concentration tested. The associated linear-regression line and
correlation coefficient are shown.
|
|
Time course of LY303366 fungicidal activity.
We compared PI
staining and SCG% for C. albicans cultures that were
incubated with LY303366 throughout a 3-h period. At 30-min intervals, aliquots of LY303366 (0.01 µg/ml)-treated cultures were either analyzed for PI fluorescence or sorted as single cells into
the wells of 96-well microculture plates. As shown in Fig. 4, percentages of PI+ cells
increased throughout the 3-h period with an attendant decrease in
SCG%. After 180 min of treatment, 78.1% of the cells were
PI+ and had an SCG% of 13.8.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Time course of the fungicidal activity of LY303366
against C. albicans. An actively growing C. albicans culture was incubated with LY303366 (0.01 µg/ml)
for a total of 3 h at 32°C. At 30-min intervals, an aliquot
of treated culture was removed and either cell sorted for determination
of SCG% ( ) or stained with PI ( ) and flow cytometrically
analyzed. Each data point represents the mean percentage of each
activity ± 1 standard error of the mean (SEM) for three separate
experiments. The mean SCG% and the mean percentage of PI+
cells for 3-h control cultures were 95 and <2, respectively.
|
|
Fungicidal effects of an initial 5-min exposure to
antifungals.
Results from a previous study with ECB analogs
(10) demonstrated that ECB analogs kill C. albicans rapidly. In that study, treatment with cilofungin caused
90% of the C. albicans cells to become PI+
within 3 h. In the present study, we modified that method to include compound removal (by washing with PBS) in order to
investigate the effects of even shorter exposure times on PI
fluorescence and reduction in CFU. The data in Table
1 demonstrate that an initial 5-min
exposure to LY303366 was equally as potent as a full 3-h exposure
period. A 5-min pulse with LY303366 at the MFC (0.01 µg/ml)
followed by a 175-min incubation in drug-free broth resulted in a mean
of 88.3% PI+ cells and an average reduction in CFU per
milliliter of 99.7%, compared with a mean of 87.0% PI+
cells and an average reduction in CFU per milliliter of 99.6% for the
3-h continuous drug treatment. While the 3-h PI assay correlates well
with the CFU and SCG% results for LY303366 (Fig. 2), in this study a
5-h PI assay underestimated the killing activity of AMB as determined
by CFU assays. Continuous or initial 5-min pulsed exposure to AMB at
2.5 µg/ml (four times the MFC) produced lower percentages of
PI+ cells than with the LY303366 treatments. An initial
5-min pulsed exposure to AMB was less effective than a continuous
5-h incubation in AMB, as measured by the PI and CFU reduction assays
(Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Determination of PI staining and CFU reduction for
C. albicans treated with LY303366 or AMB
continuously or for an initial 5-min pulse
|
|
Determination of minimum fungicidal exposure time.
We used the
pulsed-exposure technique and PI fluorescence analysis in conjunction
with CFU assays to compare the potencies and activities of selected
antifungals for C. albicans. Cultures were incubated
with antifungals for defined periods, washed with PBS, further
incubated in compound-free YPD broth (for 180 or 300 min total), and
tested by the PI fluorescence and CFU assays. The concentrations tested
were multiples of the MFCs of the antifungal compounds for each strain
as previously established by a conventional broth microdilution
technique (9). After multiple drug concentrations were
tested over various exposure periods, the minimum compound exposure
times that induced the maximal fungicidal activity of each compound
were determined; they are summarized in Table
2. The minimum exposure time required for
LY303366 at the MFC (0.01 µg/ml) to exert its maximal fungicidal
effect was only 5 min. Cilofungin at a concentration of 1.6 µg/ml
(four times the MFC) was not effective in pulsed exposures below the
full 180-min period. For AMB, the minimal exposure time determination
shown in Table 2 was based on CFU results, since the PI assay
underestimates C. albicans killing by this compound
(Table 1). A 30-min exposure (2.5 µg/ml, or four times the MFC)
was as effective in the CFU assay as a full 5-h exposure.
Effect of timing of pulsed exposure to LY303366 on fungicidal
activity.
C. albicans cultures were exposed to LY303366
(0.01 µg/ml) by three different treatment regimens in order to
help elucidate the importance of an active-growth period following
compound exposure for manifestation of fungicidal effects. Four
cultures were started, with the first being an untreated control. The
second was incubated with LY303366 continuously for 3 h. The third
culture was pulse incubated with LY303366 for 5 min, washed in PBS, and
returned to a 32°C shaker bath for 175 min. The fourth culture was
incubated without compound for 175 min, followed by the addition of
LY303366 during the last 5 min. At 180 min, aliquots from each test
culture were assayed by the PI fluorescence, CFU reduction, and SCG%
assays. Data from three such experiments are summarized in Table
3. Results obtained by all three methods
indicate that an initial 5-min pulsed exposure to LY303366, followed by
175 min of incubation without compound, was as effective in killing
C. albicans cells as a continuous 3-h exposure. In
contrast, a 5-min exposure, which occurred at the end of the 180-min
experiment and was analyzed immediately for antifungal activity,
displayed a significantly decreased fungicidal effect.
 |
DISCUSSION |
Treatment options for serious fungal infections are currently
limited. New antifungal drugs are urgently needed, especially compounds
with a fungicidal mode of action. In this study, we used flow
cytometric analysis, single-cell-sorting techniques, and standard
microbiological methods to investigate the activity of LY303366
against C. albicans and S. cerevisiae.
Our results indicate that LY303366 is a highly potent and rapidly
acting fungicidal compound. While our methods are novel, our results
are consistent with an accumulating body of knowledge regarding the
potency and broad-spectrum fungicidal activity of this promising
antifungal compound (11, 20, 26).
Advancements in flow cytometry instrumentation have pushed the
technology into microbiology laboratories worldwide. A thorough review
of flow cytometric applications for microbiology was published recently
(4). Flow cytometry offers unique advantages for studying the fungicidal activities of selected compounds against yeasts, providing the ability to examine the effects of compounds on thousands of individual cells within seconds. This type of analysis facilitates the understanding of the heterogeneous nature of yeast populations with
respect to drug sensitivity. In a previous study (10), members of our group showed how flow cytometric measurement of PI
fluorescence could distinguish the activity of fungicidal agents, such
as cilofungin, from that of a fungistatic compound such as fluconazole.
The PI method was particularly well suited for determining the extent
of fungal cell killing by cilofungin; more than 90% of the cells
treated with cilofungin became PI+ within 3 h of
treatment at the MFC. In the present study, we applied this method
to investigate the antifungal effects of a more potent ECB analog,
LY303366. Using this approach, we demonstrated an approximately 40-fold
increase in potency of LY303366 over cilofungin. Other investigators,
using standard in vitro and in vivo microbiology assays, have
demonstrated that LY303366 has potent, broad-spectrum fungicidal
activity (11, 16, 23, 29-31).
The additional cell-sorting experiments described in this paper
supported our hypothesis that LY303366-treated, PI+ yeast
cells were indeed nonviable (Fig. 2). This confirmation is important
because others have shown that certain bacteria may exhibit staining
with selected viability dyes and yet be able to recover and grow
(4, 7, 13). In addition, other studies have indicated that
treatment of yeast with the fungistatic agent fluconazole can increase
PI fluorescence slightly, yet these cells resume their growth and
exhibit normal PI-staining patterns after removal from compound
(19).
Results from the concentration response and time course experiments
(Fig. 3 and 4) demonstrate that the PI assay and single-cell sorting
for determination of SCG% complement each other. In the LY303366
concentration response experiments, PI staining correlated (r > 0.99) with decreased SCG%, further validating
the PI method for measuring fungicidal activity of LY303366 against
C. albicans and S. cerevisiae.
After confirming the lethal effects of a 3-h treatment with LY303366,
we then focused on determining the minimal exposure period sufficient
to kill C. albicans by comparing pulsed-compound exposures to continuous 3- or 5-h incubations. Using this approach, we
determined (Table 2) that binding of LY303366 to C. albicans is rapid; exposure to the MFC (0.01 µg/ml) for 5 min killed >99% of the cells. These data demonstrate that chemical
modifications of the fatty acid side chains of the ECB nucleus
(6) incorporated in the synthesis of LY303366 resulted
in an agent with much greater potency than cilofungin. The rapid
killing of yeast cells by LY303366 after a short exposure period may
contribute to its potent efficacy in vivo (3).
The rapid action and enhanced potency of LY303366 compare favorably
with those of AMB, a polyene antifungal that has been used clinically
since the 1950s (8). AMB has been reported to bind
ergosterol in fungal cell membranes within 30 min (27). Cell
membrane permeability is increased, first for potassium ions and then
for other cell constituents, resulting in cell death within hours after
exposure. Binding of AMB was recently shown to decrease yeast plasma
membrane potential within 30 min of AMB exposure (18). Flow
cytometric analysis of PI staining has been used to study AMB activity
against yeasts (22) and to investigate serum effects
(15) or synergy (21) or antagonism
(14) between antifungals. Our studies also demonstrated that
a 30-min incubation with AMB has an effect on C. albicans, an effect measured by increased PI fluorescence (Table
2). Although AMB binds rapidly, our data indicate that AMB does not
increase yeast cell membrane permeability to PI as early as LY303366
does. C. albicans cultures treated with AMB for 5 h display only one-fifth of the PI+ cells displayed by
cultures treated with LY303366 for 3 h (Table 1). Some
investigators have used deoxycholate to enhance PI entry into
AMB-treated cells (14). AMB is highly effective against most
clinical fungal isolates (17); however, nephrotoxicity limits its clinical utility. Among its effects, LY303366 targets a
fungus-specific enzyme, glucan synthase (5), which may
contribute to an improved toxicity profile.
Because LY303366 binds rapidly to yeast cells and has an inhibitory
effect on cell wall synthesis, its antifungal effects would be expected
to occur over time in a growing culture. One paradox emerged from the
pulsed-exposure experiments: while a 5-min pulsed exposure to LY303366
was shown to be sufficient to eventually kill target cells (Table 1),
deposition of single cells into microwells following 30 min of
incubation with LY303366 resulted in a smaller-than-expected decrease
in SCG% (Fig. 4). We hypothesized that active-growth conditions are
important for maximal killing activity of LY303366. To test this idea,
we conducted experiments in which cells were treated with LY303366 for
5 min, with or without an active-growth period (incubation in a shaker water bath) for 175 min in compound-free medium (Table 3). The PI
staining, CFU, and SCG% assays all indicated that a 5-min pulse with
compound without the active-growth period resulted in a significantly reduced fungicidal effect compared to the effect on cultures that were
actively grown in a shaking water bath for an additional 175 min. To
reconcile these results, we considered the fact that for each of the
three fungicidal activity assays, cells were suspended in drug-free
medium following the drug pulse. It is possible that when
LY303366-treated cells are suspended in drug-free broth, some of the
drug will come off of the cells. We hypothesize that if yeast cells
remain in log-phase growth, as promoted by the shaker bath, most will
begin cell division and, therefore, die before much drug comes off.
With static culture conditions following the drug pulse, such as the
microtiter well or agar plate, drug release could become a more
significant factor because fewer cells will divide while a
lethal-threshold level of drug remains bound to the cell. Our results
imply that yeasts growing at lower rates may require somewhat longer
exposure periods in order to be killed by this agent.
In summary, we have utilized flow cytometric analysis, cell sorting,
and standard microbiological plating methods to study the fungicidal
activities of selected antifungals against S. cerevisiae and C. albicans. Our data indicate that
cell sorting may be a valuable tool for studying and
differentiating various antifungal activities. The PI fluorescence and
cell-sorting methods provide tools for evaluating certain modes
of action that are not easily accomplished by standard microbiological
techniques. In addition, our data indicate that LY303366 is
a potent, rapidly acting antifungal agent. In our experiments, we
confirmed that LY303366-treated PI+ yeast cells are
nonviable. Our data also suggest that LY303366 works best against
actively growing yeasts. The potency and rapid action of LY303366
suggest that it may be useful for antifungal therapy of human disease.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: DC0444, Lilly
Corporate Center, Indianapolis, IN 46285. Phone: (317) 276-6048. Fax: (317) 277-2934. E-mail: Green_Lisa_J{at}lilly.com.
 |
REFERENCES |
| 1.
|
Bartlett, M. S.,
W. L. Current,
M. P. Goheen,
C. J. Boylan,
C. H. Lee,
M. M. Shaw,
S. F. Queener, and J. W. Smith.
1996.
Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.
Antimicrob. Agents Chemother.
40:1811-1816[Abstract].
|
| 2.
|
Beaulieu, D.,
J. Tang,
S. B. Yan,
J. M. Vessels,
J. A. Radding, and T. R. Parr, Jr.
1994.
Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)- -D-glucan synthase.
Antimicrob. Agents Chemother.
38:937-944[Abstract/Free Full Text].
|
| 3.
|
Current, W., and W. Turner.
1997.
Echinocandin antifungal agents, p. 315-334.
In
W. Strohl (ed.), Biotechnology of antibiotics. Marcel Dekker, Inc., New York, N.Y.
|
| 4.
|
Davey, H. M., and D. B. Kell.
1996.
Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses.
Microbiol. Rev.
60:641-696[Abstract/Free Full Text].
|
| 5.
|
Debono, M., and R. S. Gordee.
1994.
Antibiotics that inhibit fungal cell wall development.
Annu. Rev. Microbiol.
48:471-497[Medline].
|
| 6.
|
Debono, M.,
W. W. Turner,
L. LaGrandeur,
F. J. Burkhardt,
J. S. Nissen,
K. K. Nichols,
M. J. Rodriguez,
M. J. Zweifel,
D. J. Zeckner,
R. S. Gordee, et al.
1995.
Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB.
J. Med. Chem.
38:3271-3281[Medline].
|
| 7.
|
Diaper, J. P.,
K. Tither, and C. Edwards.
1992.
Rapid assessment of bacterial viability by flow cytometry.
Appl. Microbiol. Biotechnol.
38:268-272[Medline].
|
| 8.
|
Gallis, H. A.,
R. H. Drew, and W. W. Pickard.
1990.
Amphotericin B: 30 years of clinical experience.
Rev. Infect. Dis.
12:308-329[Medline].
|
| 9.
|
Gordee, R. S.,
D. J. Zeckner,
L. C. Howard,
W. E. Alborn, Jr., and M. Debono.
1988.
Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.
Ann. N. Y. Acad. Sci.
544:294-309[Medline].
|
| 10.
|
Green, L.,
B. Petersen,
L. Steimel,
P. Haeber, and W. Current.
1994.
Rapid determination of antifungal activity by flow cytometry.
J. Clin. Microbiol.
32:1088-1091[Abstract/Free Full Text].
|
| 11.
|
Krishnarao, T. V., and J. N. Galgiani.
1997.
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
Antimicrob. Agents Chemother.
41:1957-1960[Abstract].
|
| 12.
|
Kurtz, M. B.,
I. B. Heath,
J. Marrinan,
S. Dreikorn,
J. Onishi, and C. Douglas.
1994.
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)- -D-glucan synthase.
Antimicrob. Agents Chemother.
38:1480-1489[Abstract/Free Full Text]. (Erratum, 38:2516.)
|
| 13.
|
Lloyd, D., and A. J. Hayes.
1995.
Vigour, vitality and viability of microorganisms.
FEMS Microbiol. Lett.
133:1-7.
|
| 14.
|
Martin, E.,
F. Maier, and S. Bhakdi.
1994.
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.
Antimicrob. Agents Chemother.
38:1331-1338[Abstract/Free Full Text].
|
| 15.
|
Martin, E.,
U. Schlasius, and S. Bhakdi.
1992.
Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.
Med. Microbiol. Immunol.
181:117-126[Medline].
|
| 16.
|
Moore, C. B.,
K. L. Oakley, and D. W. Denning.
1997.
In vitro activity of LY303366 compared with fluconazole, flucytosine and amphotericin B against Candida spp., abstr. F-67, p. 157.
In
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 17.
|
Odds, F. C.
1996.
Resistance of clinically important yeasts to antifungal agents.
Int. J. Antimicrob. Agents
6:145-147.
|
| 18.
|
Ordonez, J. V., and N. M. Wehman.
1995.
Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay.
Cytometry
22:154-157[Medline].
|
| 19.
|
Petersen, B. H.,
L. Green,
L. Steimel,
D. Hyslop, and W. L. Current.
1993.
Use of flow cytometry for determination of minimal exposure time for effective antifungal activity of LY303366 and other antifungal compounds, abstr. 362, p. 185.
In
Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 20.
|
Pfaller, M. A.,
S. A. Messer, and S. Coffman.
1997.
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
Antimicrob. Agents Chemother.
41:763-766[Abstract].
|
| 21.
|
Pore, R. S.
1992.
Amphotericin B synergy testing by the FCST.
Curr. Microbiol.
24:171-177.
|
| 22.
|
Pore, R. S.
1990.
Antibiotic susceptibility testing of Candida albicans by flow cytometry.
Curr. Microbiol.
20:323-328.
|
| 23.
|
Rennie, R.,
C. Sand, and S. Smith.
1996.
In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species, abstr. F45, p. 107.
In
Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 24.
|
Taft, C. S.,
T. Stark, and C. P. Selitrennikoff.
1988.
Cilofungin (LY121019) inhibits Candida albicans (1-3)- -D-glucan synthase activity.
Antimicrob. Agents Chemother.
32:1901-1903[Abstract/Free Full Text].
|
| 25.
|
Tang, J., and T. R. Parr, Jr.
1991.
W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)- -D-glucan synthase.
Antimicrob. Agents Chemother.
35:99-103[Abstract/Free Full Text].
|
| 26.
|
Uzun, Ö.,
S. Kocagöz,
Y. Çetinkaya,
S. Arikan, and S. Ünal.
1997.
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
Antimicrob. Agents Chemother.
41:1156-1157[Abstract].
|
| 27.
|
Vanden Bossche, H.,
G. Willemsens, and P. Marichal.
1987.
Anti-Candida drugs the biochemical basis for their activity.
Crit. Rev. Microbiol.
15:57-72[Medline].
|
| 28.
|
Wade, J. C.
1997.
Treatment of fungal and other opportunistic infections in immunocompromised patients.
Leukemia
11(Suppl. 4):S38-S39.
|
| 29.
|
Zeckner, D.,
T. Butler,
C. Boylan,
B. Boyll,
Y. Lin,
P. Raab,
J. Schmidtke, and W. Current.
1993.
LY303366, activity in a murine systemic candidiasis model, abstr. 365, p. 186.
In
Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 30.
|
Zeckner, D.,
T. Butler,
C. Boylan,
B. Boyll,
P. Watson, and W. Current.
1995.
In vitro evaluation of LY303366 against Candida spp. clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis, abstr. F98, p. 130.
In
Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 31.
|
Zelenitsky, S.,
J. Karlowsky,
D. Hoban,
N. Laing,
T. Balko,
A. Kabani,
M. Turik, and G. Zhanel.
1997.
Activity of an investigational echinocandin, LY303366 against fluconazole susceptible and resistant Candida albicans in a multiple dose in vitro pharmacodynamic model, abstr. F-72, p. 158.
In
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
Antimicrobial Agents and Chemotherapy, April 1999, p. 830-835, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Johnson, E. M.
(2008). Issues in antifungal susceptibility testing. J Antimicrob Chemother
61: i13-i18
[Abstract]
[Full Text]
-
Sussman, A., Huss, K., Chio, L.-C., Heidler, S., Shaw, M., Ma, D., Zhu, G., Campbell, R. M., Park, T.-S., Kulanthaivel, P., Scott, J. E., Carpenter, J. W., Strege, M. A., Belvo, M. D., Swartling, J. R., Fischl, A., Yeh, W.-K., Shih, C., Ye, X. S.
(2004). Discovery of Cercosporamide, a Known Antifungal Natural Product, as a Selective Pkc1 Kinase Inhibitor through High-Throughput Screening. Eukaryot Cell
3: 932-943
[Abstract]
[Full Text]
-
Polonelli, L., Magliani, W., Conti, S., Bracci, L., Lozzi, L., Neri, P., Adriani, D., De Bernardis, F., Cassone, A.
(2003). Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis. Infect. Immun.
71: 6205-6212
[Abstract]
[Full Text]
-
Yaakov, G., Bell, M., Hohmann, S., Engelberg, D.
(2003). Combination of Two Activating Mutations in One HOG1 Gene Forms Hyperactive Enzymes That Induce Growth Arrest. Mol. Cell. Biol.
23: 4826-4840
[Abstract]
[Full Text]
-
Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., Walsh, T. J.
(2001). Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits. Antimicrob. Agents Chemother.
45: 3322-3327
[Abstract]
[Full Text]
-
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W.
(2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev.
14: 643-658
[Abstract]
[Full Text]
-
Groll, A. H., Mickiene, D., Petraitiene, R., Petraitis, V., Lyman, C. A., Bacher, J. S., Piscitelli, S. C., Walsh, T. J.
(2001). Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling. Antimicrob. Agents Chemother.
45: 2845-2855
[Abstract]
[Full Text]